Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsHarpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.
An isolated peptide comprising SEQ ID No. 2, wherein said peptide has an overall length of not more than 100 amino acids, or a pharmaceutically acceptable salt thereof.
An isolated peptide having an overall length of not more than 30 amino acids, wherein said peptide comprises a variant of SEQ ID NO:
A fusion protein, comprising SEQ ID NO:
Dependencies are inferred from the claim text.